Related Experiment Video

Updated: Jun 21, 2026

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction

Tomomi Kiyota1, Masaru Yamamoto, Huangui Xiong

  • 1Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, USA.

Plos One
|July 14, 2009
PubMed
Abstract

Insights

Chemokine (C-C motif) ligand 2 (CCL2) accelerates Alzheimer's disease (AD) symptoms by promoting amyloid-beta (Abeta) oligomerization in microglia, leading to memory deficits and synaptic dysfunction.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Neuroinflammation is linked to Alzheimer's disease (AD) pathogenesis.
  • Specific immune pathways' roles in AD require further elucidation.
  • Previous work showed CCL2 overexpression enhances microgliosis and Abeta deposition in AD mouse models.

Purpose of the Study:

  • To investigate the impact of CCL2 on cognitive and synaptic functions in AD mouse models.
  • To determine the cellular mechanisms by which CCL2 influences amyloid-beta (Abeta) pathology.

Main Methods:

  • Transgenic overexpression of CCL2 in amyloid precursor protein (APP) mutant mice.
  • Assessment of spatial and working memory.
  • Analysis of hippocampal synaptic transmission.
  • Microglial characterization and Abeta oligomer analysis.

Main Results:

  • CCL2 accelerated spatial and working memory deficits and hippocampal synaptic transmission impairments in APP mice at 2-3 months.
  • Increased microglia surrounded Abeta oligomers.
  • CCL2 facilitated Abeta uptake, intracellular oligomerization, and secretion, without suppressing degradation.

Conclusions:

  • CCL2 promotes Abeta oligomer formation within microglia.
  • These events accelerate memory dysfunction by influencing Abeta seeding in the brain.
  • CCL2 is a key mediator linking neuroinflammation to AD progression.

More Related Videos

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques10:52

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Published on: June 1, 2016

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...